MedTrace Logo

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

NCT03644056 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-05-28

No results posted yet for this study

Summary

This is a phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects with Metastatic or Locally-advanced Solid Tumors

Conditions

Interventions

DRUG

IMC-001

Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)

Sponsors & Collaborators

  • ImmuneOncia Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Yun Jeong Song, CMO/CEO · ImmuneOncia Therapeutics Inc.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-22
Primary Completion
2019-02-15
Completion
2020-05-14

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03644056 on ClinicalTrials.gov